AperçuGraphiqueProfilStatistiques clésDonnées financièresActualitésTraderScreen

Kuros Biosciences AG/  CH0325814116  /

Cboe Europe CXE
15/11/2024  17:18:12 Chg. -6.50 Volume Bid17:20:00 Demandez à17:20:00 Capitalisation boursière Dividende Y. Rapport P/E
25.00CHF -20.63% 19,018
Chiffrre d'affaires: 491,952.55		 -Bid taille: - -Ask la taille: - 912.21 Mio.CHF - -
GlobeNewswire 03/02/2022 Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
GlobeNewswire 26/10/2021 Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
GlobeNewswire 28/09/2021 Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
GlobeNewswire 15/07/2021 Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royal...
GlobeNewswire 15/07/2021 XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Bioscie...
GlobeNewswire 18/03/2021 Kuros Biosciences Reports Results for the Full Year 2020
GlobeNewswire 10/03/2021 Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences
GlobeNewswire 02/03/2021 Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
GlobeNewswire 09/09/2020 CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO...
GlobeNewswire 09/09/2020 Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
GlobeNewswire 01/09/2020 Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PT...
GlobeNewswire 12/08/2020 Kuros Biosciences Reports Results for First Half 2020
GlobeNewswire 22/07/2020 Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio
GlobeNewswire 26/03/2020 Kuros Biosciences Reports Results for the Full Year 2019
GlobeNewswire 18/03/2020 Kuros Strengthens Orthobiologics Patent Portfolio
GlobeNewswire 03/02/2020 Affimed Mourns Passing of Chief Financial Officer Dr. Florian Fischer
GlobeNewswire 30/01/2020 Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading S...
GlobeNewswire 02/10/2019 Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advan...
GlobeNewswire 24/09/2019 Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North Americ...
GlobeNewswire 03/09/2019 Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Cli...
GlobeNewswire 20/08/2019 Kuros Biosciences Reports Results for First Half 2019
GlobeNewswire 09/07/2019 Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia...
GlobeNewswire 30/04/2019 Kuros Biosciences to Propose Re-Appointment of Chairman and Board Members at Annual General Meeting
GlobeNewswire 12/04/2019 Kuros Biosciences Reports Results for the Full Year 2018
GlobeNewswire 09/04/2019 Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million